We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




Illumina and Mayo ClinicTo Develop Molecular Diagnostic Tests

By HospiMedica staff writers
Posted on 19 Jan 2007
Illumina, Inc. More...
(San Diego, CA, USA) and Mayo Clinic (Rochester, MI, USA) have signed a diagnostic collaborative agreement to enable the co-development of molecular diagnostic tests for the study of complex diseases.

Illumina will contribute its VeraCode technology and development expertise for the BeadArray and BeadXpress instrument platforms. Mayo Clinic will bring broad knowledge in clinical practice and patient outcome management, along with proficiency in establishing clinical utility of new diagnostic technologies. In addition, Mayo's ability to discover and validate biomarkers offers the potential for both parties to implement important new clinical tests.

Terms of the agreement enable the implementation of new clinical tests within Mayo's clinical practice and Mayo Medical Laboratories. Additionally, Illumina will manufacture and market tests worldwide on Illumina's BeadArray and upcoming BeadXpress Reader.

Illumina's patented BeadArray technology achieves a level of array miniaturization that allows for a new scale of experimentation. An array is a collection of miniaturized test sites arranged on a surface that permits many tests, or assays, to be performed in parallel. By arranging analytic devices into a multi-sample array of arrays format, one can process in parallel thousands to millions of assays, a throughput significantly beyond the capability of any technology known to us.

Illumina's VeraCode technology leverages the power of digital holographic codes to provide a robust detection method for multiplexed assays requiring high precision, accuracy and speed. This technology, combined with Illumina's BeadXpress Reader, supports the rapid detection and analysis of a wide range of assays with industry leading multiplexing capability.

The department of laboratory medicine and pathology at Mayo Clinic maintains an active diagnostic test development program. These activities also incorporate technologies from collaborations with diagnostic and biotechnology companies. Mayo utilizes these proven diagnostic technologies in the care of its patients and offers them to more than 5,000 health care institutions around the world through Mayo Medical Laboratories (MML). Revenue from MML testing is used to support medical education and research at Mayo Clinic.



Related Links:
Illumina
Mayo Clinic

Platinum Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
Ultrasound System
FUTUS LE
Infant Incubator
OKM 801
OR Table Accessory
Angular Accessory Rail
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.